These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 11185057

  • 21. Immunomodulatory role of Tinospora cordifolia as an adjuvant in surgical treatment of diabetic foot ulcers: a prospective randomized controlled study.
    Purandare H, Supe A.
    Indian J Med Sci; 2007 Jun; 61(6):347-55. PubMed ID: 17558098
    [Abstract] [Full Text] [Related]

  • 22. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis.
    Kantor J, Margolis DJ.
    Dermatol Surg; 2001 Apr; 27(4):347-51. PubMed ID: 11298704
    [Abstract] [Full Text] [Related]

  • 23. Topical becaplermin: new preparation. A slight short-term help for some diabetic patients.
    Prescrire Int; 2001 Dec; 10(56):167-9. PubMed ID: 11824438
    [Abstract] [Full Text] [Related]

  • 24. Platelet-derived growth factor for diabetic ulcers.
    Med Lett Drugs Ther; 1998 Jul 17; 40(1031):73-4. PubMed ID: 9698702
    [No Abstract] [Full Text] [Related]

  • 25. Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF-BB) and becaplermin gel.
    Castronuovo JJ, Ghobrial I, Giusti AM, Rudolph S, Smiell JM.
    Am J Surg; 1998 Aug 17; 176(2A Suppl):61S-67S. PubMed ID: 9777974
    [Abstract] [Full Text] [Related]

  • 26. [Becaplermin gel (Regranex gel)].
    Senet P.
    Ann Dermatol Venereol; 2004 Apr 17; 131(4):351-8. PubMed ID: 15258509
    [Abstract] [Full Text] [Related]

  • 27. Preclinical promise of becaplermin (rhPDGF-BB) in wound healing.
    LeGrand EK.
    Am J Surg; 1998 Aug 17; 176(2A Suppl):48S-54S. PubMed ID: 9777972
    [Abstract] [Full Text] [Related]

  • 28. The future of recombinant growth factors in wound healing.
    Robson MC, Mustoe TA, Hunt TK.
    Am J Surg; 1998 Aug 17; 176(2A Suppl):80S-82S. PubMed ID: 9777977
    [Abstract] [Full Text] [Related]

  • 29. Treatment of scleroderma skin ulcers using becaplermin gel and hydrocolloid membrane.
    Yoon J, Giacopelli J, Granoff D, Kobayashi W.
    J Am Podiatr Med Assoc; 2002 Jun 17; 92(6):350-4. PubMed ID: 12070235
    [Abstract] [Full Text] [Related]

  • 30. Cost-effective management of recalcitrant diabetic foot ulcers.
    Albert S.
    Clin Podiatr Med Surg; 2002 Oct 17; 19(4):483-91. PubMed ID: 12471856
    [Abstract] [Full Text] [Related]

  • 31. Pharmacotherapy of lower limb diabetic ulcers.
    Temple ME, Nahata MC.
    J Am Geriatr Soc; 2000 Jul 17; 48(7):822-8. PubMed ID: 10894324
    [Abstract] [Full Text] [Related]

  • 32. A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers.
    Mustoe TA, Cutler NR, Allman RM, Goode PS, Deuel TF, Prause JA, Bear M, Serdar CM, Pierce GF.
    Arch Surg; 1994 Feb 17; 129(2):213-9. PubMed ID: 8304833
    [Abstract] [Full Text] [Related]

  • 33. Use of becaplermin in the closure of pharyngocutaneous fistulas.
    Jakubowicz DM, Smith RV.
    Head Neck; 2005 May 17; 27(5):433-8. PubMed ID: 15776464
    [Abstract] [Full Text] [Related]

  • 34. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers.
    Robson MC, Phillips LG, Thomason A, Robson LE, Pierce GF.
    Lancet; 1992 Jan 04; 339(8784):23-5. PubMed ID: 1345953
    [Abstract] [Full Text] [Related]

  • 35. The nitric oxide connection: hyperbaric oxygen therapy, becaplermin, and diabetic ulcer management.
    Boykin JV.
    Adv Skin Wound Care; 2000 Jan 04; 13(4 Pt 1):169-74. PubMed ID: 11075012
    [Abstract] [Full Text] [Related]

  • 36. Healing and preventing the diabetic foot wound: where technology, economics and common sense converge.
    Armstrong DG.
    Indian J Med Sci; 2007 Jun 04; 61(6):324-5. PubMed ID: 17558094
    [No Abstract] [Full Text] [Related]

  • 37. [New developments in the treatment of diabetic foot ulcers].
    Bakker K, Schaper NC.
    Ned Tijdschr Geneeskd; 2000 Feb 26; 144(9):409-12. PubMed ID: 10719543
    [Abstract] [Full Text] [Related]

  • 38. Topical treatment of hypertensive leg ulcers with platelet-derived growth factor-BB: a randomized controlled trial.
    Senet P, Vicaut E, Beneton N, Debure C, Lok C, Chosidow O.
    Arch Dermatol; 2011 Aug 26; 147(8):926-30. PubMed ID: 21482863
    [Abstract] [Full Text] [Related]

  • 39. Clinicopathologic reports, case reports, and small case series: 0.01% becaplermin gel for the treatment of a chronic orbital ulcer after exenteration.
    Yassur I, Hirschbein MJ, Karesh JW.
    Arch Ophthalmol; 2001 Dec 26; 119(12):1858-9. PubMed ID: 11735804
    [No Abstract] [Full Text] [Related]

  • 40. Adenosine A2A receptor agonists promote more rapid wound healing than recombinant human platelet-derived growth factor (Becaplermin gel).
    Victor-Vega C, Desai A, Montesinos MC, Cronstein BN.
    Inflammation; 2002 Feb 26; 26(1):19-24. PubMed ID: 11936752
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.